CoChat

Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

We examined whether glucagon-like peptide-1 (GLP-1) affects β-cell mass and proliferation through neural pathways, from hepatic afferent nerves to pancreatic efferent nerves via the central nervous system, in high-fat diet (HFD)-induced obese rats. The effects of chronic administration of GLP-1 (7–36) and liraglutide, a GLP-1 receptor agonist, on pancreatic morphological alterations, c-fos expression and brain-derived neurotrophic factor (BDNF) content in the hypothalamus, and glucose metabolism were investigated in HFD-induced obese rats that underwent hepatic afferent vagotomy (VgX) and/or pancreatic efferent sympathectomy (SpX). Chronic GLP-1 (7–36) administration to HFD-induced obese rats elevated c-fos expression and BDNF content in the hypothalamus, followed by a reduction in pancreatic β-cell hyperplasia and insulin content, thus resulting in improved glucose tolerance. These responses were abolished by VgX and SpX. Moreover, administration of liraglutide similarly activated the hypothalamic neural pathways, thus resulting in a more profound amelioration of glucose tolerance than native GLP-1 (7–36). These data suggest that GLP-1 normalizes the obesity-induced compensatory increase in β-cell mass and glucose intolerance through a neuronal relay system consisting of hepatic afferent nerves, the hypothalamus, and pancreatic efferent nerves.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-05371-4

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Acute administration of GLP-1 (7–36) at more than 5 nmol/kg BW increases c-fos expression and BDNF content in the hypothalamus through hepatic afferent nerves. (a and b) Quantification of c-fos expression in the VMH (a) and BDNF content (b) in the hypothalamus of each group (n = 6). (c) Representative c-fos staining in the VMH of brain sections from each group. Red circle indicates the VMH area in the hypothalamus. *p < 0.05 vs. GLP-1 (7–36) (0 nmol/kg), Treatments: GLP-1; intraperitoneal administration of GLP-1 (7–36), Sham; sham operation, VgX; hepatic afferent vagotomy. 3 V; third ventricle. Scale bar = 100 μm.
Figure 1 Acute administration of GLP-1 (7–36) at more than 5 nmol/kg BW increases c-fos expression and BDNF content in the hypothalamus through hepatic afferent nerves. (a and b) Quantification of c-fos expression in the VMH (a) and BDNF content (b) in the hypothalamus of each group (n = 6). (c) Representative c-fos staining in the VMH of brain sections from each group. Red circle indicates the VMH area in the hypothalamus. *p < 0.05 vs. GLP-1 (7–36) (0 nmol/kg), Treatments: GLP-1; intraperitoneal administration of GLP-1 (7–36), Sham; sham operation, VgX; hepatic afferent vagotomy. 3 V; third ventricle. Scale bar = 100 μm.CC BY · PubMed Central
Figure 2 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) also increases c-fos expression and BDNF content in the hypothalamus through hepatic afferent nerves. (a) Representative c-fos staining of brain sections from each group. Red circle indicates the VMH area in the hypothalamus. (b and c) Quantification of c-fos expression in the VMH (b) and BDNF content in the hypothalamus (c) of each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36), Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; sham operation, VgX; hepatic afferent vagotomy. 3 V; third ventricle. Scale bar = 100 μm.
Figure 2 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) also increases c-fos expression and BDNF content in the hypothalamus through hepatic afferent nerves. (a) Representative c-fos staining of brain sections from each group. Red circle indicates the VMH area in the hypothalamus. (b and c) Quantification of c-fos expression in the VMH (b) and BDNF content in the hypothalamus (c) of each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36), Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; sham operation, VgX; hepatic afferent vagotomy. 3 V; third ventricle. Scale bar = 100 μm.CC BY · PubMed Central
Figure 3 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) restores obesity-induced alterations in β-cell mass and proliferation in islets through hepatic afferent nerves. (a) Representative insulin staining (left row) and Ki-67 staining (right row) performed on pancreas sections from each group. (b and c) Insulin-positive area (b) and percentage of proliferating β-cells (c) in each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; sham operation, VgX; hepatic afferent vagotomy, PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36). Scale bar = 100 μm.
Figure 3 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) restores obesity-induced alterations in β-cell mass and proliferation in islets through hepatic afferent nerves. (a) Representative insulin staining (left row) and Ki-67 staining (right row) performed on pancreas sections from each group. (b and c) Insulin-positive area (b) and percentage of proliferating β-cells (c) in each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; sham operation, VgX; hepatic afferent vagotomy, PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36). Scale bar = 100 μm.CC BY · PubMed Central
Figure 4 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) restores the obesity-induced enlargement of β-cell mass and improves glucose metabolism through pancreatic efferent nerves. (a and b) Representative insulin staining in islets (a) and insulin-positive area (b) in each group (n = 6). (c) Blood glucose (upper) and plasma insulin (lower) levels during the glucose tolerance tests in each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36), Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; preservation of pancreatic efferent sympathetic nerve with PBS administration, SpX; pancreatic efferent sympathectomy with 6-OHDA administration. Scale bar = 100 μm.
Figure 4 Chronic administration of GLP-1 (7–36) (5 nmol/kg BW) restores the obesity-induced enlargement of β-cell mass and improves glucose metabolism through pancreatic efferent nerves. (a and b) Representative insulin staining in islets (a) and insulin-positive area (b) in each group (n = 6). (c) Blood glucose (upper) and plasma insulin (lower) levels during the glucose tolerance tests in each group (n = 6). *p < 0.05 vs. Standard (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, PBS) group, $ p < 0.05 vs. HFD (Sham, GLP-1) group. Treatments: PBS; intraperitoneal administration of PBS, GLP-1; intraperitoneal administration of GLP-1 (7–36), Standard; fed with standard diet, HFD; fed with high-fat diet, Sham; preservation of pancreatic efferent sympathetic nerve with PBS administration, SpX; pancreatic efferent sympathectomy with 6-OHDA administration. Scale bar = 100 μm.CC BY · PubMed Central
Figure 5 Chronic administration of liraglutide increases c-fos expression and BDNF content in the hypothalamus, restores β-cell mass and improves glucose metabolism through hepatic afferent nerves. (a) Representative c-fos staining performed on brain sections derived from each group. Red circle indicates the VMH area in the hypothalamus. 3 V; third ventricle. Scale bar = 100 μm. (b and c) Quantification of c-fos expression in the VMH (b) and BDNF content in the hypothalamus (c) of each group (n = 6). (d) Representative insulin staining performed with pancreas sections and quantification of the insulin-positive area from each group (n = 6). Scale bar = 100 μm. (e) Blood glucose (upper) and plasma insulin (lower) levels during the glucose tolerance tests in each group (n = 6). *p < 0.05 vs. HFD (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, Liraglutide) group. Treatments: PBS; intraperitoneal administration of PBS, Liraglutide; intraperitoneal administration of liraglutide, Sham; sham operation, VgX; hepatic afferent vagotomy. HFD; fed with high-fat diet.
Figure 5 Chronic administration of liraglutide increases c-fos expression and BDNF content in the hypothalamus, restores β-cell mass and improves glucose metabolism through hepatic afferent nerves. (a) Representative c-fos staining performed on brain sections derived from each group. Red circle indicates the VMH area in the hypothalamus. 3 V; third ventricle. Scale bar = 100 μm. (b and c) Quantification of c-fos expression in the VMH (b) and BDNF content in the hypothalamus (c) of each group (n = 6). (d) Representative insulin staining performed with pancreas sections and quantification of the insulin-positive area from each group (n = 6). Scale bar = 100 μm. (e) Blood glucose (upper) and plasma insulin (lower) levels during the glucose tolerance tests in each group (n = 6). *p < 0.05 vs. HFD (Sham, PBS) group, # p < 0.05 vs. HFD (Sham, Liraglutide) group. Treatments: PBS; intraperitoneal administration of PBS, Liraglutide; intraperitoneal administration of liraglutide, Sham; sham operation, VgX; hepatic afferent vagotomy. HFD; fed with high-fat diet.CC BY · PubMed Central
Figure 6 Schematic model of the neuronal relay mediating intra-organ communication. GLP-1 secreted from L cells in the small intestine stimulates the hypothalamus indirectly through the activation of hepatic afferent nerves and directly through crossing the BBB. Activated hypothalamic neurons stimulate efferent nerves innervating the pancreas, which modulate β-cells via adrenergic receptors. In addition, GLP-1 also acts directly on β-cells through GLP-1R.
Figure 6 Schematic model of the neuronal relay mediating intra-organ communication. GLP-1 secreted from L cells in the small intestine stimulates the hypothalamus indirectly through the activation of hepatic afferent nerves and directly through crossing the BBB. Activated hypothalamic neurons stimulate efferent nerves innervating the pancreas, which modulate β-cells via adrenergic receptors. In addition, GLP-1 also acts directly on β-cells through GLP-1R.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 14

Metadata

Authors
Ando, H., Gotoh, K., Fujiwara, K., Anai, M., Chiba, S., Masaki, T., Kakuma, T., & Shibata, H.
Affiliations
Oita University (JP)
Corresponding author
Gotoh, Koro
Venue
Scientific Reports
Published
2017-07-17
Volume
7
Issue
1
Pages
5578-5578
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2734426870
Cited by
14
References
48
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2018: 3
FWCI
1.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucagon-like peptide-1, GLP-1 receptor agonists, liraglutide, beta-cell mass, beta-cell hyperplasia, brain-derived neurotrophic factor, Fos expression, glucose tolerance, high-fat diet-induced obesity
MeSH terms
Liraglutide, Animals, Glucose, Hypothalamus, Injections, Intraperitoneal, Neural Pathways, Obesity, Sympathectomy, Vagotomy, Proto-Oncogene Proteins c-fos, Rats, Sprague-Dawley, Glucose Intolerance, Brain-Derived Neurotrophic Factor, Cell Size, Cell Proliferation, Insulin-Secreting Cells, Rats, Glucagon-Like Peptide 1, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats. https://app.cochat.ai/papers/10.1038/s41598-017-05371-4
The paper
Ando, H., Gotoh, K., Fujiwara, K., Anai, M., Chiba, S., Masaki, T., Kakuma, T., & Shibata, H. (2017). Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats. Scientific Reports. https://doi.org/10.1038/s41598-017-05371-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.